Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.

Molecular-targeted therapy has shown promise as a treatment for advanced osteosarcoma (OS). Sorafenib (SOR), a multikinase inhibitor, is the approved systemic drug of choice for OS, but has demonstrated limited benefits due to its toxicity and other adverse effects. Therapy strategies for reducing toxicity include using lower doses of SOR in combination with other complementary agents. Cisplatin (CDDP) has been shown to be a promising anticancer drug against various types of cancer including OS. In the present study, SOR was combined with CDDP to determine whether this combinatorial treatment suppressed tumor growth thereby simultaneously reducing doses of the two drugs for the treatment of OS. Human Saos-2 OS cells were treated with SOR and CDDP, alone and in combination, and the effect of these treatments on cell proliferation, colony formation, cell cycle, apoptosis, migration, and invasion, and involvement in receptor signaling, as well as tumor growth ability in nude mice was determined. It was found that the combination of low concentrations of SOR and CDDP significantly suppressed the cell proliferation, colony formation, migration and invasion, and induced cell apoptosis and cell cycle arrest in the G0/G1 stage, and suppressed tumor growth in a nude mouse model compared to the actions of either agent alone. The results also showed that SOR in combination with CDDP significantly suppressed the phosphorylation of extracellular signal-regulated kinase (ERK), which may contribute to the inhibition of tumor growth. These results suggested that SOR in combination with CDDP acts synergistically in the treatment of OS.

[1]  Hao Lin,et al.  The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells. , 2014, Gene.

[2]  Jun Tang,et al.  Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism , 2014, Tumor Biology.

[3]  Yang Yao,et al.  Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute , 2014, Oncology letters.

[4]  J. Mei,et al.  VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment , 2014, Cell Biochemistry and Biophysics.

[5]  Zhihong Li,et al.  Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. , 2014, Oncology reports.

[6]  I. Miller,et al.  Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. , 2014, Oncology reports.

[7]  N. Martínez‐López,et al.  Autophagy proteins regulate ERK phosphorylation , 2013, Nature Communications.

[8]  G. Ottaviani,et al.  Sociooccupational and physical outcomes more than 20 years after the diagnosis of osteosarcoma in children and adolescents , 2013, Cancer.

[9]  N. Tamaki,et al.  Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model , 2013, Oncology letters.

[10]  N. Yang,et al.  Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling , 2013, Molecular and Cellular Biochemistry.

[11]  Masayo Umebayashi,et al.  Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. , 2013, Anticancer research.

[12]  S. Ferrari,et al.  The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models , 2013, Clinical Cancer Research.

[13]  S. Warmann,et al.  Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts , 2012, British Journal of Cancer.

[14]  P. Dileo,et al.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Gelderblom,et al.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? , 2011, European journal of cancer.

[16]  L. Tang,et al.  Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide , 2011, Asia-Pacific journal of clinical oncology.

[17]  C. Dive,et al.  Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents. , 2011, Oncology reports.

[18]  O. Fodstad,et al.  Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, Cisplatin, and Ifosfamide , 2009, Clinical Cancer Research.

[19]  E. Kleinerman,et al.  Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma , 2009, Cancer.

[20]  Jia-jia Ma,et al.  XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[21]  P. Choong,et al.  Osteosarcoma treatment: state of the art , 2009, Cancer and Metastasis Reviews.

[22]  M. Lacouture,et al.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  John H. Healey,et al.  Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group , 2008 .

[24]  Jeffrey W. Clark,et al.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.

[25]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[26]  S. Wilhelm,et al.  Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. , 2006, Seminars in oncology.

[27]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[29]  S. Abe,et al.  Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis , 2002, Cancer Chemotherapy and Pharmacology.

[30]  A. Borkhardt,et al.  Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines , 2002, Cancer Chemotherapy and Pharmacology.

[31]  Michael Fraser,et al.  Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[32]  K. Yeh,et al.  Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. , 2002, Biochemical pharmacology.

[33]  J. Hansson,et al.  The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis , 2001, Melanoma research.

[34]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[35]  D. Mercola,et al.  Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line* , 1999, The Journal of Biological Chemistry.

[36]  Jian Kang,et al.  Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[37]  G. Ottaviani,et al.  The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.

[38]  Mohd Fahad Ullah,et al.  Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[39]  P. Philip,et al.  Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Safety and Efficacy of Sorafenib in the Treatment of Hepatocellular Carcinoma , 2022 .